Janssen Submits Marketing Authorisation Application to the

Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor,1 will become the...

Related Keywords

Belgium , United States , Beerse , Region Flamande , American , Janssen Pharmaceutica , Tanakam Sonpavde , Kiran Patel , Janssen Cilag Gmb , Martin Vogel , Clinical Development , Janssen Pharmaceutical Companies , Astex Therapeutics , Astex Announces New Drug Discovery Alliance , American Society Of Clinical Oncology , None Of The Janssen Pharmaceutical Companies , Johnson , Companies Of Johnson , Janssen Research Development In Phase , Janssen Research Development , Drug Administration , European Medicines Agency , Janssen Pharmaceutical Companies Of Johnson , Astex Pharmaceuticals , Late Breaking Presentation Session , Marketing Authorisation Application , Area Lead Oncology , Clinical Oncology , Vice President , Solid Tumors , Janssen Research , New Drug Application , Bacillus Calmette Gu , Pharmaceutical Companies , Infectious Diseases , Janssen Cilag Gmbh , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Locally Advanced , Metastatic Urothelial , Bladder Cancer Prognosis , Survival Rates , Erdafitinib Compared With Vinflunine , Participants With Advanced Urothelial Cancer , Selected Fibroblast Growth Factor Receptor , Gene Aberrations , Erdafitinib Versus Investigator Choice , Participants Who Received Bacillus Calmette Gu , Participants With Metastatic , Locally Advanced Urothelial , Locally Advanced Urothelial Cancer , Text View , Participants With Advanced Solid Tumors , Fibroblast Growth Factor Receptor , Gene Alterations , Erdafitinib Intravesical Delivery System , Localized Bladder , Urothelial Carcinoma , Transduct Target Ther , Rev Clin , Janssen Emea ,